%0 Journal Article
%T Oral treatment experience in multiple sclerosis at Antalya Training and Research Hospital
%J -
%D 2019
%X Purpose: Our aim was to share our oral treatment experience in multiple sclerosis and how we decided to choose the right treatment for our patients. Materials and methods: We analyzed multiple sclerosis patients who were admitted to neurology clinic between 2012-2018. Demographic features, treatments that were used before initiating oral therapies, in which conditions the treatments were changed to oral therapies (increased relaps rate, progression, activation on magnetic resonance imaging, patient¡¯s choice, adverse events with the previous treatment), the duration of the disease and the oral treatment, Expanded Disability Status Scale (EDSS) scores were all recorded. Results: 550 patients with a definite clinical diagnosis of MS according to the 2010 McDonald criteria were enrolled. 108 (19.6%) patients were receiving oral treatment for multiple sclerosis. 53 patients (49.1%) were receiving fingolimod, 34 patients (31.5%) were receiving dimethylfumarate, 21 patients (19.4%), were receiving teriflunomide. The most evident cause for changing the treatment was the increased relaps rate. Conclusion: Although the ratio (19.6%) seemed to be lower than the ratio from whole Turkey (41%), the timing of the treatment change have been shown to be in therapeutic window
%K multipl skleroz
%K fingolimod
%K dimetilfumarat
%K oral tedavi
%K teriflunomid
%U http://dergipark.org.tr/patd/issue/45448/500441